Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms
Authors: Malin Hultcrantz, Magnus Björkholm, Ola Landgren, Sigurdur Y. Kristinsson, Therese M.L. Andersson
Journal: Annals of Internal Medicine (2018)

Letters21 August 2018Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative NeoplasmsMalin Hultcrantz, MD, PhD, Magnus Björkholm, MD, PhD, Ola Landgren, MD, PhD, Sigurdur Y. Kristinsson, MD, PhD, and Therese M.L. Andersson, MSc, PhDMalin Hultcrantz, MD, PhDKarolinska University Hospital and Karolinska Institutet, Stockholm, Sweden (M.H., M.B.)Search for more papers by this author, Magnus Björkholm, MD, PhDKarolinska University Hospital and Karolinska Institutet, Stockholm, Sweden (M.H., M.B.)Search for more papers by this author, Ola Landgren, MD, PhDMemorial Sloan-Kettering Cancer Center, New York, New York (O.L.)Search for more papers by this author, Sigurdur Y. Kristinsson, MD, PhDUniversity of Iceland and Landspitali National University Hospital, Reykjavik, Iceland (S.Y.K.)Search for more papers by this author, and Therese M.L. Andersson, MSc, PhDKarolinska Institutet, Stockholm, Sweden (T.M.A.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0245 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree that the mechanisms behind thrombosis in MPNs are multifactorial and that further research into their pathophysiology is needed. As Drs. Zhao and Schooling state, the hematocrit level and changes in the leukocyte and platelet counts and their properties likely contribute to the increased risk for thrombosis in patients with MPN and possibly also in the general population (1, 2). We unfortunately were not able to assess hematocrit levels, hemolysis activity, or the level of sex hormones, because laboratory results were not recorded in the registers used in the study. Overall, men did have a higher incidence ...References1. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22-33. [PMID: 23216616] doi:10.1056/NEJMoa1208500 CrossrefMedlineGoogle Scholar2. Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease—the Framingham study: a 34-year follow-up. Am Heart J. 1994;127:674-82. [PMID: 8122618] CrossrefMedlineGoogle Scholar3. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell. 2016;167:1415-29. [PMID: 27863252] doi:10.1016/j.cell.2016.10.042 CrossrefMedlineGoogle Scholar4. Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41:450-4. [PMID: 19287385] doi:10.1038/ng.341 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden (M.H., M.B.)Memorial Sloan-Kettering Cancer Center, New York, New York (O.L.)University of Iceland and Landspitali National University Hospital, Reykjavik, Iceland (S.Y.K.)Karolinska Institutet, Stockholm, Sweden (T.M.A.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-0028. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRisk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms Malin Hultcrantz , Magnus Björkholm , Paul W. Dickman , Ola Landgren , Åsa R. Derolf , Sigurdur Y. Kristinsson , and Therese M.L. Andersson Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms Jie V. Zhao and C. Mary Schooling Metrics Cited byIs There a Role for Direct Oral Anticoagulants in the Primary and Secondary Prevention of Myeloproliferative Neoplasm Associated Thrombosis?Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2 -Mutated Myeloproliferative NeoplasmsPrevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulantsRisk of infections in patients with myeloproliferative neoplasms—a population-based cohort study of 8363 patientsAmong classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19Editor's Choice – European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb IschaemiaRecurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms 21 August 2018Volume 169, Issue 4Page: 268KeywordsDisclosureGeneticsHaplotypesHazard ratioHematocritPlateletsResearch laboratoriesRisk managementSex hormonesThrombosis ePublished: 21 August 2018 Issue Published: 21 August 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...